Combination immunotherapy for high-risk resected and metastatic melanoma patients.

Riker, Adam I; Rossi, Gabriela R; Masih, Prerna; Alsfeld, L C; Denham, Fiona; Tennant, Lucinda; Ramsey, W Jay; Vahanian, Nicholas N; Link, Charles J

Riker, Adam I; Rossi, Gabriela R; Masih, Prerna; Alsfeld, L C; Denham, Fiona; Tennant, Lucinda; Ramsey, W Jay; Vahanian, Nicholas N; Link, Charles J.

Afiliación

Riker AI; Department of Surgery, Advocate Cancer Institute, Advocate Christ Medical Center, Oak Lawn, IL.
Rossi GR; NewLink Genetics, Ames, IA.
Masih P; NewLink Genetics, Ames, IA.
Alsfeld LC; Department of Internal Medicine, Medical University of South Carolina, Charleston, SC.
Denham F; Department of General Surgery, Carilion Clinic, Roanoke, VA.
Tennant L; NewLink Genetics, Ames, IA.
Ramsey WJ; NewLink Genetics, Ames, IA.
Vahanian NN; NewLink Genetics, Ames, IA.
Link CJ; NewLink Genetics, Ames, IA.

Ochsner J ; 14(2): 164-74, 2014.

Article en En | MEDLINE | ID: mdl-24940124

Palabras clave

Alpha-galactosyl epitope; immunotherapy; melanoma; peginterferon alfa-2b; vitiligo

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Ochsner J Año: 2014 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google